July 22 Puma Biotechnology Inc said its
experimental cancer drug met its main goal in a late-stage
trial, sending its shares up about 186 percent in extended
The drug neratinib, codenamed PB272, is being studied as a
potential adjuvant treatment for breast cancer.
Adjuvant treatment, or additional treatment, is given after
the primary treatment.
Treatment with neratinib showed a statistically significant
improvement in disease-free survival of 33 percent versus
patients who on placebo, according to the trial data.
The patients were treated with neratinib after adjuvant
treatment with the cancer drug trastuzumab in women with
early-stage HER2-positive breast cancer.
Puma said it intends to file for marketing approval in the
first half of 2015.
Shares of the company were had closed at $59.03 on the New
York Stock Exchange on Tuesday.
(Reporting by Shailesh Kuber; Editing by Joyjeet Das)